Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 31 peer-reviewed journal articles Updated
Medical Genetics

Understanding Legius Syndrome: A Guide for Patients and Families

At a Glance

Legius syndrome is a rare genetic condition caused by a SPRED1 gene mutation. It primarily presents with café-au-lait spots and skin freckling. While it looks very similar to Neurofibromatosis type 1 (NF1), Legius syndrome is much milder and lacks the tumor risks associated with NF1. Genetic testing is required for an accurate diagnosis.

If you have spent late nights searching the internet for answers about multiple skin spots, you likely encountered frightening information about tumors, vision loss, and complex medical needs. For many individuals and parents, the term “café-au-lait spots” becomes a gateway to learning about Neurofibromatosis type 1 (NF1), a condition that can involve significant health risks [1].

However, receiving a diagnosis of Legius syndrome often comes as a profound relief. While it looks very similar to NF1 on the surface, Legius syndrome is a distinct and much milder condition [2][1]. Understanding why these two conditions look alike—and why they are so different—is the first step in navigating your care with confidence.

Why the Confusion Happens

Legius syndrome and NF1 are “look-alike” conditions because they both affect the same biological communication system in the body, known as the RAS-MAPK pathway [3][4]. This pathway helps control how cells grow and divide.

In Legius syndrome, a change (mutation) in the SPRED1 gene causes this pathway to be slightly overactive [3]. This overactivity leads to the hallmark skin findings: multiple flat, tan-to-brown spots and freckling in the skinfolds [2][1]. Because these skin findings are also the primary early signs of NF1, many people are initially suspected of having NF1 [1]. It is only through specialized genetic testing that doctors can confirm the problem is with the SPRED1 gene rather than the NF1 gene [5].

How Rare is Legius Syndrome?

Legius syndrome is much rarer than NF1, which is part of why many general doctors may not be as familiar with it. While NF1 affects about 1 in 3,000 people, the incidence of Legius syndrome is estimated to be between 1 in 19,000 and 1 in 41,000 individuals [6].

Using This Guide

This guide is designed to help you, your child, and your family understand what Legius syndrome means for your health, development, and future. Please use the links below to navigate through the topics:

01

Symptoms and Development: What to Watch For

Learn about the physical and cognitive symptoms of Legius syndrome. Understand café-au-lait spots, ADHD risks, seizure monitoring, and proactive management.

02

The Crucial Difference: Legius Syndrome vs. NF1

Learn the crucial differences between Legius syndrome and NF1. Understand why genetic testing for SPRED1 and NF1 mutations is essential for a proper diagnosis.

03

Building Your Care Team and Long-Term Support

Learn how to build a medical care team for Legius syndrome. Discover long-term support strategies, school accommodations, and genetic counseling options.

Common questions in this guide

How is Legius syndrome different from Neurofibromatosis type 1 (NF1)?
While both conditions cause café-au-lait spots and skinfold freckling, Legius syndrome is generally much milder. It does not carry the same risks for tumors, vision loss, and complex medical needs that are often associated with NF1.
What causes Legius syndrome?
Legius syndrome is caused by a genetic mutation in the SPRED1 gene. This mutation makes a cellular communication system called the RAS-MAPK pathway slightly overactive, which leads to the characteristic skin findings.
Can doctors diagnose Legius syndrome just by looking at my skin spots?
No, because the skin spots associated with Legius syndrome look identical to the early signs of NF1. Specialized genetic testing is required to confirm whether the genetic mutation is in the SPRED1 gene or the NF1 gene.
How rare is Legius syndrome?
Legius syndrome is considered very rare, affecting an estimated 1 in 19,000 to 1 in 41,000 individuals. This makes it significantly less common than NF1.
What should parents monitor in a child diagnosed with Legius syndrome?
Along with routine health check-ups, it is important to monitor the child's developmental milestones. Your care team may recommend evaluating for potential learning or behavioral challenges as the child grows.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How did the genetic testing distinguish between a SPRED1 mutation and an NF1 mutation?
  2. 2.Since Legius syndrome does not have the same tumor risks as NF1, which standard NF1 screenings can we safely skip?
  3. 3.What specific symptoms or developmental milestones should we be monitoring over time?
  4. 4.Are there resources or specialists you recommend for evaluating potential learning or behavioral challenges?
  5. 5.Given the long-term outlook, how frequently should we schedule routine follow-up appointments?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (6)
  1. 1

    Legius Syndrome and its Relationship with Neurofibromatosis Type 1.

    Denayer E, Legius E

    Acta dermato-venereologica 2020; (100(7)):adv00093 doi:10.2340/00015555-3429.

    PMID: 32147744
  2. 2

    Novel causative variants in Legius syndrome: SPRED1 Genotype spectrum expansion.

    Chelleri C, Brolatti N, De Marco P, et al.

    American journal of medical genetics. Part A 2024; (194(12)):e63824 doi:10.1002/ajmg.a.63824.

    PMID: 39031930
  3. 3

    Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.

    Hirata Y, Brems H, Suzuki M, et al.

    The Journal of biological chemistry 2016; (291(7)):3124-34 doi:10.1074/jbc.M115.703710.

    PMID: 26635368
  4. 4

    Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.

    Führer S, Tollinger M, Dunzendorfer-Matt T

    Journal of molecular biology 2019; (431(19)):3889-3899 doi:10.1016/j.jmb.2019.07.038.

    PMID: 31401120
  5. 5

    Diagnostic value of multiple café-au-lait macules for neurofibromatosis 1 in Chinese children.

    Yao R, Wang L, Yu Y, et al.

    The Journal of dermatology 2016; (43(5)):537-42 doi:10.1111/1346-8138.13169.

    PMID: 26458495
  6. 6

    Moyamoya syndrome in a child with Legius syndrome: Introducing a cerebral vasculopathy to the SPRED1 phenotype?

    Pabst L, Carroll J, Lo W, Truxal KV

    American journal of medical genetics. Part A 2021; (185(1)):223-227 doi:10.1002/ajmg.a.61921.

    PMID: 33078527

This page provides an overview of Legius syndrome for educational purposes only. Always consult a geneticist or your healthcare provider for an accurate diagnosis, genetic testing interpretation, and a personalized care plan.

Get notified when new evidence is published on Legius syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.